Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Multi-regional, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Activity of HCB303 in Participants With Advanced Malignancies

NCT07859228 is registered in ClinicalTrials.gov with FBD Biologics Limited as lead sponsor.

NCT NCT07859228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07859228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Multi-regional, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Activity of HCB303 in Participants With Advanced Malignancies
Lead sponsor
FBD Biologics Limited
Phase
Phase 1
Overall status
Not yet recruiting
Start date
February 28, 2027
Completion date
February 28, 2030
Enrollment
150 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies